Holen Sie sich die Stockscreener-App
237.27
2.46%
5.69
Handel nachbörslich:
233.23
-4.04
-1.70%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt RMD?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$231.58
Offen:
$231
24-Stunden-Volumen:
2.32M
Relative Volume:
2.61
Marktkapitalisierung:
$34.83B
Einnahmen:
$4.81B
Nettoeinkommen (Verlust:
$1.11B
KGV:
38.52
EPS:
6.16
Netto-Cashflow:
$1.35B
1W Leistung:
-0.52%
1M Leistung:
-1.77%
6M Leistung:
+11.25%
1J Leistung:
+36.39%
1-Tages-Spanne:
$231.00
$238.60
1-Wochen-Bereich:
$229.94
$245.19
52-Wochen-Spanne:
$164.12
$260.49
Resmed Inc Stock (RMD) Company Profile
Firmenname
Resmed Inc
Sektor
Telefon
(858) 746-2400
Adresse
9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA
Vergleichen Sie RMD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RMD
Resmed Inc
|
237.27 | 34.83B | 4.81B | 1.11B | 1.35B | 7.55 |
|
ISRG
Intuitive Surgical Inc
|
524.43 | 186.79B | 7.87B | 2.24B | 586.00M | 6.22 |
|
BDX
Becton Dickinson Co
|
227.68 | 65.83B | 20.18B | 1.71B | 3.07B | 5.94 |
|
ALC
Alcon Inc
|
84.76 | 41.92B | 9.76B | 1.16B | 665.00M | 2.34 |
|
WST
West Pharmaceutical Services Inc
|
331.40 | 24.00B | 2.88B | 499.60M | 321.60M | 6.74 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-13 | Eingeleitet | Stifel | Hold |
| 2024-09-24 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-09-18 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2024-09-04 | Herabstufung | Needham | Buy → Hold |
| 2024-06-25 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-06-24 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-02-06 | Fortgesetzt | KeyBanc Capital Markets | Overweight |
| 2023-10-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-10-12 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-10-09 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-09-29 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2023-09-06 | Hochstufung | Needham | Hold → Buy |
| 2023-09-05 | Herabstufung | UBS | Buy → Neutral |
| 2023-08-01 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-05-23 | Eingeleitet | UBS | Buy |
| 2023-04-14 | Eingeleitet | Mizuho | Buy |
| 2023-01-17 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-10-28 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-10-20 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-10-12 | Eingeleitet | Jefferies | Hold |
| 2022-09-08 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-08-15 | Herabstufung | CLSA | Buy → Outperform |
| 2022-08-12 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-08-12 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-08-12 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-06-06 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-04-06 | Eingeleitet | Wolfe Research | Outperform |
| 2022-01-31 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-01-31 | Hochstufung | Goldman | Neutral → Buy |
| 2022-01-28 | Hochstufung | RBC Capital Mkts | Underperform → Sector Perform |
| 2022-01-24 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-01-24 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-01-13 | Hochstufung | CLSA | Outperform → Buy |
| 2022-01-13 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2021-12-21 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-12-06 | Hochstufung | Macquarie | Neutral → Outperform |
| 2021-10-22 | Hochstufung | CLSA | Underperform → Outperform |
| 2021-08-02 | Herabstufung | CLSA | Outperform → Sell |
| 2021-08-02 | Herabstufung | Needham | Buy → Hold |
| 2021-07-28 | Hochstufung | Jefferies | Underperform → Hold |
| 2021-07-26 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-07-14 | Eingeleitet | RBC Capital Mkts | Underperform |
| 2021-06-28 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-06-22 | Hochstufung | Macquarie | Neutral → Outperform |
| 2021-06-22 | Eingeleitet | Robert W. Baird | Neutral |
| 2021-06-21 | Bestätigt | Needham | Buy |
| 2021-06-16 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2021-06-09 | Hochstufung | CLSA | Sell → Outperform |
| 2021-05-21 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-05-11 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-04-30 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-03-16 | Hochstufung | Needham | Hold → Buy |
| 2020-11-02 | Hochstufung | UBS | Neutral → Buy |
| 2020-10-30 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2020-10-27 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2020-08-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-06-17 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-05-01 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2020-05-01 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2020-02-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-03 | Eingeleitet | CLSA | Underperform |
| 2020-01-31 | Herabstufung | UBS | Buy → Neutral |
| 2020-01-10 | Eingeleitet | Oppenheimer | Perform |
| 2019-11-22 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2019-07-29 | Hochstufung | UBS | Neutral → Buy |
| 2019-07-16 | Herabstufung | UBS | Buy → Neutral |
| 2019-05-06 | Hochstufung | UBS | Neutral → Buy |
| 2019-04-18 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2019-01-25 | Herabstufung | Goldman | Buy → Neutral |
| 2019-01-25 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2018-10-26 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2018-07-02 | Eingeleitet | Goldman | Buy |
Alle ansehen
Resmed Inc Aktie (RMD) Neueste Nachrichten
Y Intercept Hong Kong Ltd Reduces Position in ResMed Inc. (NYSE:RMD) - MarketBeat
$18.97 Bn Mechanical Ventilator Market Opportunities and - GlobeNewswire
ResMed Inc.'s (NYSE:RMD) institutional investors lost 4.5% last week but have benefitted from longer-term gains - Simply Wall St
ResMed Inc. stock rises Thursday, outperforms market - MarketWatch
ResMed Inc. stock falls Wednesday, underperforms market - MarketWatch
YieldBoost ResMed From 0.9% To 6.8% Using Options - Nasdaq
ResMed Inc Director Expands Stock Holdings - MSN
XTX Topco Ltd Has $301,000 Holdings in ResMed Inc. (NYSE:RMD) - MarketBeat
With 74% institutional ownership, ResMed Inc. (NYSE:RMD) is a favorite amongst the big guns - Yahoo Finance
Franklin Resources Inc. Increases Stock Holdings in ResMed Inc. (NYSE:RMD) - MarketBeat
2,216 Shares in ResMed Inc. (NYSE:RMD) Acquired by World Investment Advisors LLC - MarketBeat
ResMed's SWOT analysis: sleep tech giant faces GLP-1 threat, AI opportunity - Investing.com
ResMed Inc. stock rises Tuesday, outperforms market - MarketWatch
2 ASX companies with the traits of a long-term winner - Morningstar.com.au
Is ResMed Stock Outperforming the Nasdaq? - Nasdaq
Is ResMed Stock Outperforming The Nasdaq? - Barchart
ResMed Inc. stock rises Monday, outperforms market - MarketWatch
Assistive Technology Market Is Booming Worldwide 2024-2031: Dynavox Systems LLC., Invacare Corporation, ResMed - EIN News
Weight-loss drugs draw Americans back to the doctor - Marketscreener.com
The Global Medical Cannula Market Is Poised for Significant Growth USD 447.0 Million by 2034 at a 6.9% of CAGR, driven by Rising Demand for Medical Procedures and Advanced Healthcare Solutions | FMI - GlobeNewswire Inc.
What is William Blair's Estimate for ResMed Q2 Earnings? - MarketBeat
Stifel Initiates Coverage of ResMed Inc.Depositary Receipt () (RSMDF) with Hold Recommendation - MSN
Wellington Management Group LLP Purchases 15,772 Shares of ResMed Inc. (NYSE:RMD) - MarketBeat
ResMed Inc. (NYSE:RMD) Receives $227.91 Average PT from Brokerages - MarketBeat
Toronto Dominion Bank Has $12.02 Million Stock Holdings in ResMed Inc. (NYSE:RMD) - MarketBeat
American Trust Makes New $690,000 Investment in ResMed Inc. (NYSE:RMD) - MarketBeat
Virtu Financial LLC Decreases Stake in ResMed Inc. (NYSE:RMD) - MarketBeat
We Ran A Stock Scan For Earnings Growth And ResMed (NYSE:RMD) Passed With Ease - Yahoo Finance
ResMed Inc. stock falls Friday, underperforms market - MarketWatch
Why ResMed (RMD) is a Top Value Stock for the Long-Term - Yahoo Finance
ResMed (NYSE:RMD) Now Covered by Analysts at Stifel Nicolaus - MarketBeat
ResMed, The Company Behind Making Sleep Apnea Machines, has Developed The $120 Kontor Head Strap For The Apple Vision Pro To Alleviate Head Strain - Wccftech
Zacks.com featured highlights include InterDigital, ResMed, Greenbrier Companies, Charles River Associates and Kontoor Brands - Yahoo Finance
ResMed Inc. stock falls Thursday, underperforms market - MarketWatch
Geode Capital Management LLC Acquires 380,383 Shares of ResMed Inc. (NYSE:RMD) - MarketBeat
ResMed Inc. (NYSE:RMD) Shares Purchased by Nomura Asset Management Co. Ltd. - MarketBeat
ResMed Inc. stock rises Wednesday, still underperforms market - MarketWatch
ResMed Inc (RMD) CFO Brett Sandercock Sells 1,000 Shares - GuruFocus.com
ResMed CFO Sandercock sells $244,230 in stock By Investing.com - Investing.com South Africa
ResMed CFO Sandercock sells $244,230 in stock - Investing.com
ResMed's SWOT analysis: sleep tech giant faces GLP-1 drug challenge - Investing.com
Stifel Financial Corp Has $14 Million Stock Position in ResMed Inc. (NYSE:RMD) - MarketBeat
National Bank of Canada FI Acquires 19,120 Shares of ResMed Inc. (NYSE:RMD) - MarketBeat
'Huge opportunity' ahead for this ASX 200 healthcare stock - MSN
13,712 Shares in ResMed Inc. (NYSE:RMD) Bought by Executive Wealth Management LLC - MarketBeat
iA Global Asset Management Inc. Has $1.40 Million Stock Position in ResMed Inc. (NYSE:RMD) - MarketBeat
What is Zacks Research's Forecast for ResMed Q2 Earnings? - MarketBeat
William Blair Brokers Boost Earnings Estimates for ResMed - MarketBeat
Returns on Capital Paint A Bright Future For ResMed (NYSE:RMD) - Yahoo Finance
Insiders At ResMed Sold US$17m In Stock, Alluding To Potential Weakness - Simply Wall St
Quantinno Capital Management LP Has $6.02 Million Stake in ResMed Inc. (NYSE:RMD) - MarketBeat
Finanzdaten der Resmed Inc-Aktie (RMD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.69%
1.18%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):